Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Precipio's ROE % for the quarter that ended in Mar. 2026 was -40.44%. Precipio's PB Ratio for the quarter that ended in Mar. 2026 was 0.72.
Precipio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -56.17%.
Precipio ROE % Adjusted to Book Value Related Terms
Precipio ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Precipio's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:TGK vs QUCY, IDXG, BIOQ: ROE % Adjusted to Book Value Comparison
For the Diagnostics & Research subindustry, Precipio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Precipio ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Precipio's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -56.17% mean?
Precipio (STU:TGK) has a ROE % Adjusted to Book Value of -56.17% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Precipio and its competitors.
Is Precipio's ROE % Adjusted to Book Value too high?
Precipio's current ROE % Adjusted to Book Value is -56.17%. Overall, Precipio has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Precipio's ROE % Adjusted to Book Value compare to QUCY and IDXG?
Precipio's ROE % Adjusted to Book Value of -56.17% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Precipio and its competitors. Precipio's current ROE % Adjusted to Book Value is -56.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Precipio stock overvalued right now?
Precipio (STU:TGK) has a current ROE % Adjusted to Book Value of -56.17%. The stock's GF Value™ is €2.26, compared to a current price of €4.96 — trading 119.5% above its estimated fair value. The current ROE % Adjusted to Book Value is -56.17%. Precipio's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Precipio (STU:TGK), the current ROE % Adjusted to Book Value is -56.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Precipio (STU:TGK) Overvalued in 2026?
Based on GuruFocus' analysis, Precipio stock appears to be overvalued.
The current stock price of €4.96 is trading 119.5% above its estimated GF Value™ of €2.26.
Key valuation signals for STU:TGK:
ROE % Adjusted to Book Value: -56.17%
GF Value™: €2.26 vs. price of €4.96 (119.5% above fair value)
No single metric tells the full story. See the STU:TGK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.
51GF Score
Get the complete analysis for STU:TGK
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:TGK has been successfully added to your 
